Equillium Inc at JMP Securities Life Sciences Virtual Conference Transcript
Perfect. Hi, good morning, everyone. Welcome to our JMP annual Life Sciences Conference. And I'm pleased to kick off my session with Equillium Bio. We have Bruce Steel, CEO; and Dolca Thomas, CMO, here with us today. So really glad to have you guys here. Thank you.
So they are going to tell us about their lead asset, itolizumab, targeting CD6-ALCAM pathway. It's being developed for multiple severe immuno inflammatory diseases on the heels of some new results that were recently presented from the Phase 1 EQUATE trial in first-line acute GVHD at EHA. And we will take it from there. Thank you.
Great. Thank you. Good morning. It's a pleasure to be here. Dolca and I are thrilled to have the opportunity to provide you the updates today. And as you mentioned, we will focus the conversation a bit on the recent EHA update that was provided by Dr. John Koreth, the lead investigator in our EQUATE study, in the first-line treatment of acute GVHD -- that was Friday at EHA. We will be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
